Physician profile
Raphny A Johnson
NPI 1164766903
$4,475.08
in general payments reported to CMS, 2019-2025
39 companies · $637 in 2025
The $637 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $312 · 2021: $724 · 2022: $916 · 2023: $963 · 2024: $551 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,150.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $617.33 | 2022-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $594.76 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $407.19 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $360.34 | 2019-2025 | |
| Medtronic, INC. | $353.40 | 2022-2025 | V-Loc 180, Ligasure, Truclear |
| Millicent US INC | $287.11 | 2020-2025 | Intrarosa, Femring, Femlyv |
| Evofem Biosciences, INC. | $219.65 | 2021-2025 | Phexxi, Solosec, Phexx |
| Biogen, INC. | $178.54 | 2024-2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $146.81 | 2019-2021 | |
| Organon LLC | $126.61 | 2021-2025 | Nexplanon |
| Shield Therapeutics INC | $119.10 | 2022-2025 | Accrufer |
| Lupin INC. | $108.20 | 2019-2021 | |
| Myovant Sciences INC. | $106.26 | 2021-2022 | |
| Coopersurgical, INC. | $72.90 | 2023-2025 | Wallach Cryosurgical Equipment, Paragard T 380a |
| Avion Pharmaceuticals | $69.22 | 2019-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $62.72 | 2021-2024 | Tyblume |
| Aspira Women'S Health INC | $58.16 | 2023-2024 | Ova1 |
| Davol INC. | $57.20 | 2022 | |
| Merck Sharp & Dohme LLC | $55.37 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $42.29 | 2023 | Myfembree |
| Therapeuticsmd, INC. | $41.64 | 2019-2020 | |
| Avanos Medical | $36.04 | 2023 | On-Q* Pump and Accessories |
| Amag Pharmaceuticals, INC. | $34.39 | 2019-2020 | |
| Allergan, INC. | $30.57 | 2019-2020 | |
| Ethicon US, LLC | $29.75 | 2025 | Stratafix |
| Scynexis, INC. | $25.56 | 2022 | |
| Aroa Biosurgery Incorporated | $24.50 | 2025 | |
| Mylan Pharmaceuticals INC. | $23.84 | 2022 | |
| Daiichi Sankyo INC. | $22.37 | 2020 | |
| Pfizer INC. | $19.75 | 2024 | |
| Smith+Nephew, INC. | $19.33 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $19.21 | 2021 | |
| Lilly USA, LLC | $16.62 | 2025 | Zepbound |
| Mission Pharmacal Company | $16.34 | 2023 | Citranatal |
| Agile Therapeutics, INC. | $15.88 | 2021 | |
| Exact Sciences Corporation | $15.10 | 2023 | Cologuard Collection Kit |
| Covidien LP | $14.75 | 2019 | |
| Medicem INC. | $14.26 | 2020 | |
| Ascend Therapeutics US, LLC | $12.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raphny Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.